Sermorelin: A Former FDA Drug, Now a Compounded Peptide

Sermorelin is GHRH (1-29), the shortest fragment of the natural growth hormone-releasing hormone that still retains full biological activity. Of all the compounds in the GH-axis category, sermorelin is the one with a genuine pharmaceutical pedigree: it was developed, trialled and brought to market as a licensed medicine decades before the modern research-peptide scene existed.

That distinction matters because it shapes everything about how sermorelin is treated today. Where most peptides discussed online have never cleared a regulator, sermorelin earned two separate FDA approvals under the brand name Geref, both held by EMD Serono. The first, in 1990, was for a diagnostic product used to test pituitary function. The second, in 1997, was for treating idiopathic growth hormone deficiency in children with growth failure. The product was then voluntarily pulled from the US market in 2008, a decision the FDA later formally determined was not made for reasons of safety or effectiveness.

The bottom line: Sermorelin is the 29-amino-acid active core of GHRH and a former FDA-approved drug, which is the key fact separating it from its unapproved relatives.

Sermorelin binds the GHRH receptor on the pituitary’s somatotroph cells and prompts them to release a burst of the body’s own growth hormone, which the liver then converts into rising IGF-1. Because it acts a step upstream of growth hormone itself, the pituitary’s normal feedback controls stay in the loop, so the body can still throttle GH output if levels climb too high.

The defining feature of sermorelin’s pharmacology is how briefly it acts. It is cleared from the bloodstream within minutes, producing a single sharp rise in GH that peaks roughly 30 to 60 minutes after administration before subsiding. That short, clean spike is exactly why it worked as a diagnostic agent in the Geref era: clinicians could give a measured stimulus, draw blood at set intervals, and read how much GH the pituitary was capable of producing. It is also the property most often contrasted with longer-acting GHRH analogues, which sustain elevated signalling for days rather than restoring a natural pulse.

The bottom line: Sermorelin produces a short, self-limiting pulse of the body’s own GH while leaving the pituitary’s feedback system intact.

Sermorelin’s evidence base is stronger than most peptides in its class because it was studied to the standard required for drug approval, but the bulk of that evidence supports its original indications, not the wellness uses it is marketed for now.

The approval-era evidence

The clinical work that won Geref its approvals established two things: that a measured dose of sermorelin reliably stimulates GH release, making it a valid test of pituitary reserve, and that it improved growth outcomes in children with idiopathic GH deficiency. This is human, regulator-reviewed evidence, which is a meaningfully higher tier than the animal data or self-reported outcomes that underpin many other peptides. It was solid enough that, after Geref left the market, clinicians lamented the loss of the GHRH stimulation test as a diagnostic tool.

The gap for modern uses

The uses sermorelin is most often sold for today, such as anti-ageing, body-composition improvement and “GH optimisation” in healthy adults, sit on much thinner ground. There are supportive Phase 2 findings on lean mass and metabolic markers, but no Phase 3 trials have tested these applications, and there is no FDA-approved sermorelin indication for any of them. The compound has real research backing for what it was authorised to do and limited controlled evidence for what most buyers actually want from it.

Use	Evidence Tier	Status
Diagnosing pituitary GH reserve	Regulator-reviewed (diagnostic trials)	Former indication (Geref Diagnostic)
Childhood GH deficiency	Regulator-reviewed (paediatric growth data)	Former indication (Geref, 1997)
Adult anti-ageing / body composition	Phase 2 only, no Phase 3	Off-label, not approved

The bottom line: Sermorelin has approval-grade evidence for diagnosing and treating GH deficiency, but the wellness uses driving its current popularity have never been validated in a Phase 3 trial.

Sermorelin’s regulatory position is the most comfortable of any growth hormone peptide, and the reason is its history as a licensed medicine. Because it was a previously authorised product, it never landed on the restricted compounding list that has tied up newer peptides, and US pharmacies can still prepare it on a valid prescription.

Country	Marketed Drug?	Practical Status
United States	No (withdrawn)	Legally compounded off-label with a prescription
United Kingdom	No	Unlicensed; unlawful to supply for human use
Australia	No	Prescription-only class; import restricted

In the US, sermorelin can be compounded under both section 503A (patient-specific orders from state-licensed pharmacies) and 503B (FDA-registered outsourcing facilities). It was never placed in the FDA’s restricted compounding category, which is the practical difference between sermorelin and peptides that are currently blocked; that two-tier category system is explained in our piece on the FDA’s compounding classifications, and the broader national framework in our guide to how the US regulates peptides. Prescribing it for anti-ageing or body composition is off-label, which is legal when a licensed physician judges it appropriate, but it shifts responsibility onto the prescriber.

Outside the US the comfort evaporates. In the UK, sermorelin has no MHRA authorisation, and supplying it as an unlicensed prescription-only medicine is unlawful under the Human Medicines Regulations 2012; see our overview of the UK position on research peptides. Australia’s TGA classifies GHRH-class peptides as prescription-only and restricts personal importation, covered in our guide to Australian peptide rules. Across all three jurisdictions, sermorelin is prohibited in tested sport: the World Anti-Doping Agency lists it under category S2 at all times.

The bottom line: Sermorelin is legally compoundable in the US because it was once an approved drug, but it remains unlicensed in the UK and Australia and banned in competitive sport.

Sermorelin was generally well tolerated across its approval-era use, and its short duration of action and intact feedback loop are often cited as reasons it is considered gentler than directly administering growth hormone. The most common reported effects are local: pain, redness or swelling at the injection site. Less frequent reactions include flushing, headache and occasional dizziness.

The more meaningful caveats are about context rather than the molecule. First, large-scale, long-term safety data in healthy adults using sermorelin for wellness purposes remain limited, because that population was never the subject of the registration trials. Second, the safety profile that earned Geref its approval applies to a pharmaceutical-grade product made under regulated manufacturing, which is not the same thing as compounded or, worse, research-channel material of unverified quality.

The bottom line: Sermorelin has a reassuring short-term safety record from its approved use, but that record assumes regulated product, prescriber supervision and a population it was actually tested in.

Sermorelin is the reference point for the wider GHRH-analogue family, and comparing it to its relatives is the clearest way to understand the trade-offs.

• CJC-1295 is the long-acting cousin engineered from the same GHRH (1-29) backbone, trading sermorelin’s natural short pulse for days-long signalling and a far weaker regulatory standing. We weigh the two directly in our side-by-side look at the two GHRH analogues.
• Ipamorelin reaches the same goal of raising GH but through the ghrelin receptor rather than the GHRH receptor; our ipamorelin guide covers how the two receptor pathways are sometimes combined.
• Tesamorelin is the GHRH analogue that, unlike sermorelin, still holds an active FDA approval, granted in 2010 for HIV-associated abdominal fat; see our overview of the currently approved GHRH drug.